1. Breast cancer 5 year survival rates (UK, 1975) by stage at diagnosis

2. 5-year survival in breast cancer (Europe; 1990) 020406080100 Switzerland Finland France Italy Netherlands Germany Denmark England Spain Scotland Estonia Poland Five-year survival (%) J Nat Cancer Inst 1995; 87: 1209 5-year survival (%) No. of patients75.773.571.470.869.968.468.162.562.561.858.843.92,24311,1232,4983,5952,6533,35917,49860,3901,04311,2612,3871,089

3. Breast cancer demographics Anderson WF et al. Breast Cancer Res Treat 2002; 76: 27–36 24.9 56.9 35.7 64.3 41.4 50.1 8.5 75.1 63.3 20.1 79.9 28.8 65.1 6.1 ER-positive ER-negative Proportion of patients (%) Mean age (years) Age at diagnosis (%) <50  50 Tumour size (%) >2.0 cm  2.0 cm unknown Patients (n=82,488) ER = oestrogen receptor

4. Placebo Tamoxifen Breast cancer continuum: consistency of results on 5 years of tamoxifen

5. Breast cancer incidence and mortality England France Germany Total EU USA n 10,846 10,811 17,692 73,592 39,800 n 34,176 35,726 48,098 210,631 211,300 Incidence Mortality Jemal A et al. CA Cancer J Clin 2003; 53: 5–26; Cancer Research UK. Cancer Stats – Incidence & Mortality UK, April 2003; Ferlay et al. IARC Press, 1999

6. Changes in incidence and mortality from breast cancer (UK, 1994) Incidence In the UK in 1992, the incidence of breast cancer was 40% higher than in 1979 Incidence of breast cancer in the UK (age 50–64) increased steeply following the introduction of screening in 1988 Mortality 110 100 90 80 0 110 100 90 80 0 1950607080879094 Year Screening introduced Age-standardised mortality from breast cancer in women aged 55-69, England and Wales, 1950-94 Quinn M, et al. Br Med J 1995; 311: 1391-1395

7. Improved Outlook in Early Breast Cancer: Indirect Comparison of ATAC data with EBCTCG 1995 Overview 1 (Hormone Receptor +ve Patients >50 Years) Estimated percentage still without recurrence as first event 100 80 0 012345+ years 90 70 84.6% 70.5% 3-year event-free rate: 90% 92% *ATAC data truncated at 42 months 1 EBCTCG. The Lancet 1998; 351: 1451–1467 Anastrozole (ATAC data) Tamoxifen (ATAC data) Tamoxifen (EBCTCG overview) Control (EBCTCG overview)

8. Cancer Research UK, 2003 Number of new cases Age at diagnosis 450 400 350 300 250 200 150 100 50 0 6000 5000 4000 3000 2000 1000 0 85+ 80- 84 75- 79 70- 74 65- 69 60- 64 55- 59 50- 54 45- 49 40- 44 35- 39 30- 34 25- 29 20- 24 15- 19 10- 14 0- 4 5- 9 Rate per 100,000 population number rates Number of new breast cancer cases diagnosed and age-specific rates per 100,000 population, UK, 1999

9. Survival from time of tumour recurrence: in all patients with advanced breast cancer 1974-1979 1980-1984 1985-1989 1990-1994 1995-2000

10. Survival in advanced breast cancer Year of 1st recurrence Median Survival (months) 3 year OS (%) 5 year OS (%) 1974 - 197915 10 1980 - 1984172714 1985 - 1989223722 1990 - 1994274329 1995 - 2000586344